ABCELLERA BIOLOGICS (8QQ) — Financial Flexibility Index

Latest as of June 2026: 0.07x

ABCELLERA BIOLOGICS (8QQ) has a Financial Flexibility Index of 0.07x as of June 2026. Free cash flow of €28.05 Million (operating CF €25.92 Million minus capex €2.13 Million) represents 0% of total liabilities (€411.56 Million). Check ABCELLERA BIOLOGICS (8QQ) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Financial Flexibility Index

0.07x
Free Cash Flow / Total Liabilities

Free Cash Flow

€28.05 Million
Operating CF − Capex

Total Liabilities

€411.56 Million
EUR

Capital Expenditures

€2.13 Million
EUR

ABCELLERA BIOLOGICS Financial Flexibility Index (2021–2025)

Historical Financial Flexibility Index trend for ABCELLERA BIOLOGICS across 5 annual periods. For the full cash flow conversion analysis, see 8QQ operating cash flow.

Annual Financial Flexibility Index for ABCELLERA BIOLOGICS (2021–2025)

Year-by-year free cash flow to debt coverage for ABCELLERA BIOLOGICS. Explore debt repayment capacity of ABCELLERA BIOLOGICS to assess how comfortably operating cash covers total debt obligations.

Year Flexibility Index Free Cash Flow (EUR) Operating CF Total Liabilities YoY Change
2025 -0.23x €-88.52 Million €-131.29 Million €390.05 Million ▼ -129.1%
2024 -0.10x €-30.16 Million €-108.56 Million €304.47 Million ▼ -198.9%
2023 0.10x €33.63 Million €-43.88 Million €335.78 Million ▼ -91.2%
2022 1.14x €350.02 Million €277.36 Million €307.63 Million ▲ +9.9%
2021 1.03x €303.04 Million €244.58 Million €292.84 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities